Key result
Durvalumab monotherapy induced acute immune-mediated myocarditis in a 67-year-old male with lung squamous cell carcinoma, which rapidly resolved following glucocorticoid treatment.
Why the study?
Myocarditis following PD-L1 inhibitor therapy is characterized by low incidence and high mortality.
Does durvalumab monotherapy cause acute myocarditis in patients with lung squamous cell carcinoma?
Population
A 67-year-old male with lung squamous cell carcinoma complicated with empyema
Design
Case report
Authors
Loading...
Durvalumab may trigger immune-mediated myocarditis; case supports glucocorticoid response but leaves optimal surveillance open.
Case Report (n=1)
Does durvalumab monotherapy cause acute myocarditis in patients with lung squamous cell carcinoma?
Durvalumab monotherapy can cause acute, potentially fatal immune-mediated myocarditis that may respond rapidly to glucocorticoid therapy.
Zhou et al. (2022) conducted a case report in Lung squamous cell carcinoma (n=1). Durvalumab was evaluated. Durvalumab monotherapy induced acute immune-mediated myocarditis in a 67-year-old male with lung squamous cell carcinoma, which rapidly resolved following glucocorticoid treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: